- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-Flag magnetic beads
- Anti-Flag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Magnetic Separator
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
NU7441 (KU-57788)
NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.
NU7441 (KU-57788) Chemical Structure
CAS No. 503468-95-9
Purity & Quality Control
Batch:
Purity:
99.94%
99.94
Products often used together with NU7441 (KU-57788)
NU7441 and KU-0060648 reduce the frequency of the non-homologous end joining (NHEJ) pathway while increasing the rate of homology-directed recombination (HDR).
NU7441 and KU-55933 combination treatment significantly increase X-ray cytotoxicity in MDCK cells.
NU7441 and NU7026 are potent DNA-PK inhibitors that inhibit the DSBs repair pathway and enhance the sensitivity of cancer cells to ionizing radiation or chemo-potentiation.
NU7441 (KU-57788) Related Products
| Related Products | NU7026 AZD7648 CC-115 Nedisertib (M3814) KU-0060648 YU238259 LTURM34 | Click to Expand |
|---|---|---|
| Related Compound Libraries | FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library | Click to Expand |
Signaling Pathway
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| NCI-H1770 | Growth Inhibition Assay | IC50=0.02143 μM | SANGER | |||
| A172 | Growth Inhibition Assay | IC50=0.15316 μM | SANGER | |||
| NCI-H526 | Growth Inhibition Assay | IC50=0.28407 μM | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | IC50=0.32345 μM | SANGER | |||
| HuO-3N1 | Growth Inhibition Assay | IC50=0.46636 μM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=0.60994 μM | SANGER | |||
| SK-N-AS | Growth Inhibition Assay | IC50=0.62216 μM | SANGER | |||
| LoVo | Growth Inhibition Assay | IC50=0.86749 μM | SANGER | |||
| LAMA-84 | Growth Inhibition Assay | IC50=0.98833 μM | SANGER | |||
| CTB-1 | Growth Inhibition Assay | IC50=1.11546 μM | SANGER | |||
| KP-N-YS | Growth Inhibition Assay | IC50=1.14231 μM | SANGER | |||
| HH | Growth Inhibition Assay | IC50=1.18093 μM | SANGER | |||
| CHL-1 | Growth Inhibition Assay | IC50=1.21368 μM | SANGER | |||
| NB7 | Growth Inhibition Assay | IC50=1.24745 μM | SANGER | |||
| HL-60 | Growth Inhibition Assay | IC50=1.3819 μM | SANGER | |||
| 639-V | Growth Inhibition Assay | IC50=1.44128 μM | SANGER | |||
| NCI-H1793 | Growth Inhibition Assay | IC50=1.4584 μM | SANGER | |||
| NEC8 | Growth Inhibition Assay | IC50=1.5535 μM | SANGER | |||
| PA-1 | Growth Inhibition Assay | IC50=1.58294 μM | SANGER | |||
| D-423MG | Growth Inhibition Assay | IC50=1.69361 μM | SANGER | |||
| NCI-H292 | Growth Inhibition Assay | IC50=1.74013 μM | SANGER | |||
| SK-MEL-1 | Growth Inhibition Assay | IC50=1.79479 μM | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | IC50=2.14146 μM | SANGER | |||
| SK-MEL-3 | Growth Inhibition Assay | IC50=2.1649 μM | SANGER | |||
| MHH-PREB-1 | Growth Inhibition Assay | IC50=2.16609 μM | SANGER | |||
| BFTC-905 | Growth Inhibition Assay | IC50=2.16687 μM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=2.19909 μM | SANGER | |||
| G-361 | Growth Inhibition Assay | IC50=2.2168 μM | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | IC50=2.21888 μM | SANGER | |||
| DEL | Growth Inhibition Assay | IC50=2.35564 μM | SANGER | |||
| MV-4-11 | Growth Inhibition Assay | IC50=2.3739 μM | SANGER | |||
| SK-NEP-1 | Growth Inhibition Assay | IC50=2.38783 μM | SANGER | |||
| RS4-11 | Growth Inhibition Assay | IC50=2.56023 μM | SANGER | |||
| HuH-7 | Growth Inhibition Assay | IC50=2.56702 μM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=2.61338 μM | SANGER | |||
| KG-1 | Growth Inhibition Assay | IC50=2.67924 μM | SANGER | |||
| KALS-1 | Growth Inhibition Assay | IC50=2.69633 μM | SANGER | |||
| VMRC-RCZ | Growth Inhibition Assay | IC50=2.77328 μM | SANGER | |||
| SK-UT-1 | Growth Inhibition Assay | IC50=3.1531 μM | SANGER | |||
| SW962 | Growth Inhibition Assay | IC50=3.20352 μM | SANGER | |||
| DBTRG-05MG | Growth Inhibition Assay | IC50=3.28085 μM | SANGER | |||
| PANC-08-13 | Growth Inhibition Assay | IC50=3.41278 μM | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | IC50=3.41341 μM | SANGER | |||
| SK-MEL-30 | Growth Inhibition Assay | IC50=3.42598 μM | SANGER | |||
| 697 | Growth Inhibition Assay | IC50=3.44993 μM | SANGER | |||
| NY | Growth Inhibition Assay | IC50=3.45022 μM | SANGER | |||
| ES7 | Growth Inhibition Assay | IC50=3.46729 μM | SANGER | |||
| JVM-3 | Growth Inhibition Assay | IC50=3.48077 μM | SANGER | |||
| U031 | Growth Inhibition Assay | IC50=3.59368 μM | SANGER | |||
| BHT-101 | Growth Inhibition Assay | IC50=3.59985 μM | SANGER | |||
| 8305C | Growth Inhibition Assay | IC50=3.61736 μM | SANGER | |||
| MG-63 | Growth Inhibition Assay | IC50=3.62676 μM | SANGER | |||
| NOS-1 | Growth Inhibition Assay | IC50=3.65312 μM | SANGER | |||
| YH-13 | Growth Inhibition Assay | IC50=3.87189 μM | SANGER | |||
| LXF-289 | Growth Inhibition Assay | IC50=3.91041 μM | SANGER | |||
| GOTO | Growth Inhibition Assay | IC50=3.9149 μM | SANGER | |||
| EKVX | Growth Inhibition Assay | IC50=4.22524 μM | SANGER | |||
| CAL-51 | Growth Inhibition Assay | IC50=4.24854 μM | SANGER | |||
| AN3-CA | Growth Inhibition Assay | IC50=4.25813 μM | SANGER | |||
| IA-LM | Growth Inhibition Assay | IC50=4.27935 μM | SANGER | |||
| KU-19-19 | Growth Inhibition Assay | IC50=4.32921 μM | SANGER | |||
| A704 | Growth Inhibition Assay | IC50=4.40888 μM | SANGER | |||
| RH-18 | Growth Inhibition Assay | IC50=4.44953 μM | SANGER | |||
| IST-MEL1 | Growth Inhibition Assay | IC50=4.58263 μM | SANGER | |||
| LU-134-A | Growth Inhibition Assay | IC50=4.59685 μM | SANGER | |||
| SF126 | Growth Inhibition Assay | IC50=4.60715 μM | SANGER | |||
| EFO-27 | Growth Inhibition Assay | IC50=4.66525 μM | SANGER | |||
| SN12C | Growth Inhibition Assay | IC50=4.71898 μM | SANGER | |||
| L-363 | Growth Inhibition Assay | IC50=4.77116 μM | SANGER | |||
| MEL-HO | Growth Inhibition Assay | IC50=4.77989 μM | SANGER | |||
| TYK-nu | Growth Inhibition Assay | IC50=4.80128 μM | SANGER | |||
| MDA-MB-415 | Growth Inhibition Assay | IC50=5.00314 μM | SANGER | |||
| HCC70 | Growth Inhibition Assay | IC50=5.03939 μM | SANGER | |||
| IGROV-1 | Growth Inhibition Assay | IC50=5.25292 μM | SANGER | |||
| NCI-H1355 | Growth Inhibition Assay | IC50=5.296 μM | SANGER | |||
| 23132-87 | Growth Inhibition Assay | IC50=5.32024 μM | SANGER | |||
| NB69 | Growth Inhibition Assay | IC50=5.3242 μM | SANGER | |||
| HSC-2 | Growth Inhibition Assay | IC50=5.41773 μM | SANGER | |||
| KYSE-410 | Growth Inhibition Assay | IC50=5.47636 μM | SANGER | |||
| GCIY | Growth Inhibition Assay | IC50=5.51378 μM | SANGER | |||
| A427 | Growth Inhibition Assay | IC50=5.53661 μM | SANGER | |||
| ChaGo-K-1 | Growth Inhibition Assay | IC50=5.56599 μM | SANGER | |||
| PFSK-1 | Growth Inhibition Assay | IC50=5.62194 μM | SANGER | |||
| MLMA | Growth Inhibition Assay | IC50=5.83606 μM | SANGER | |||
| RVH-421 | Growth Inhibition Assay | IC50=6.07338 μM | SANGER | |||
| LB1047-RCC | Growth Inhibition Assay | IC50=6.17522 μM | SANGER | |||
| MHH-NB-11 | Growth Inhibition Assay | IC50=6.32721 μM | SANGER | |||
| J-RT3-T3-5 | Growth Inhibition Assay | IC50=6.63291 μM | SANGER | |||
| UM-UC-3 | Growth Inhibition Assay | IC50=6.64334 μM | SANGER | |||
| IST-SL1 | Growth Inhibition Assay | IC50=6.69369 μM | SANGER | |||
| NB14 | Growth Inhibition Assay | IC50=6.79761 μM | SANGER | |||
| NBsusSR | Growth Inhibition Assay | IC50=6.82502 μM | SANGER | |||
| D-263MG | Growth Inhibition Assay | IC50=6.91068 μM | SANGER | |||
| NCI-H2347 | Growth Inhibition Assay | IC50=6.93213 μM | SANGER | |||
| ES8 | Growth Inhibition Assay | IC50=6.97588 μM | SANGER | |||
| 786-0 | Growth Inhibition Assay | IC50=7.09786 μM | SANGER | |||
| EPLC-272H | Growth Inhibition Assay | IC50=7.16246 μM | SANGER | |||
| CAPAN-1 | Growth Inhibition Assay | IC50=7.24359 μM | SANGER | |||
| NCI-H82 | Growth Inhibition Assay | IC50=7.26659 μM | SANGER | |||
| G-402 | Growth Inhibition Assay | IC50=7.30051 μM | SANGER | |||
| SW982 | Growth Inhibition Assay | IC50=7.30203 μM | SANGER | |||
| OVCAR-4 | Growth Inhibition Assay | IC50=7.31328 μM | SANGER | |||
| KARPAS-299 | Growth Inhibition Assay | IC50=7.32622 μM | SANGER | |||
| MIA-PaCa-2 | Growth Inhibition Assay | IC50=7.36823 μM | SANGER | |||
| AU565 | Growth Inhibition Assay | IC50=7.59833 μM | SANGER | |||
| GAMG | Growth Inhibition Assay | IC50=7.64131 μM | SANGER | |||
| HuO9 | Growth Inhibition Assay | IC50=7.71743 μM | SANGER | |||
| ACN | Growth Inhibition Assay | IC50=7.7433 μM | SANGER | |||
| RO82-W-1 | Growth Inhibition Assay | IC50=7.74533 μM | SANGER | |||
| NKM-1 | Growth Inhibition Assay | IC50=7.74955 μM | SANGER | |||
| CAL-12T | Growth Inhibition Assay | IC50=7.94352 μM | SANGER | |||
| FADU | Growth Inhibition Assay | IC50=8.03654 μM | SANGER | |||
| NCI-H28 | Growth Inhibition Assay | IC50=8.16962 μM | SANGER | |||
| LCLC-97TM1 | Growth Inhibition Assay | IC50=8.21122 μM | SANGER | |||
| CHP-134 | Growth Inhibition Assay | IC50=8.24185 μM | SANGER | |||
| HT-1080 | Growth Inhibition Assay | IC50=8.25093 μM | SANGER | |||
| PC-3 | Growth Inhibition Assay | IC50=8.27392 μM | SANGER | |||
| SNU-449 | Growth Inhibition Assay | IC50=8.2793 μM | SANGER | |||
| VA-ES-BJ | Growth Inhibition Assay | IC50=8.34686 μM | SANGER | |||
| HT | Growth Inhibition Assay | IC50=8.3649 μM | SANGER | |||
| HOS | Growth Inhibition Assay | IC50=8.37589 μM | SANGER | |||
| KNS-62 | Growth Inhibition Assay | IC50=8.37762 μM | SANGER | |||
| OAW-42 | Growth Inhibition Assay | IC50=8.95964 μM | SANGER | |||
| A549 | Growth Inhibition Assay | IC50=9.09612 μM | SANGER | |||
| CAKI-1 | Growth Inhibition Assay | IC50=9.1661 μM | SANGER | |||
| HCC1937 | Growth Inhibition Assay | IC50=9.69865 μM | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | IC50=9.70137 μM | SANGER | |||
| DU-4475 | Growth Inhibition Assay | IC50=9.96939 μM | SANGER | |||
| EM-2 | Growth Inhibition Assay | IC50=10.2426 μM | SANGER | |||
| NCI-H1755 | Growth Inhibition Assay | IC50=10.2428 μM | SANGER | |||
| NCI-H1437 | Growth Inhibition Assay | IC50=10.5725 μM | SANGER | |||
| VM-CUB-1 | Growth Inhibition Assay | IC50=10.6164 μM | SANGER | |||
| A2058 | Growth Inhibition Assay | IC50=10.6404 μM | SANGER | |||
| BPH-1 | Growth Inhibition Assay | IC50=10.7145 μM | SANGER | |||
| NB5 | Growth Inhibition Assay | IC50=10.7559 μM | SANGER | |||
| G-401 | Growth Inhibition Assay | IC50=10.7626 μM | SANGER | |||
| CAL-72 | Growth Inhibition Assay | IC50=10.8094 μM | SANGER | |||
| SK-MEL-28 | Growth Inhibition Assay | IC50=10.8202 μM | SANGER | |||
| C32 | Growth Inhibition Assay | IC50=10.8347 μM | SANGER | |||
| NCI-H1155 | Growth Inhibition Assay | IC50=10.8376 μM | SANGER | |||
| BB49-HNC | Growth Inhibition Assay | IC50=10.8586 μM | SANGER | |||
| GMS-10 | Growth Inhibition Assay | IC50=10.8971 μM | SANGER | |||
| K5 | Growth Inhibition Assay | IC50=10.9071 μM | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | IC50=11.0559 μM | SANGER | |||
| HTC-C3 | Growth Inhibition Assay | IC50=11.0714 μM | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | IC50=11.0723 μM | SANGER | |||
| NCI-H1563 | Growth Inhibition Assay | IC50=11.1011 μM | SANGER | |||
| CAL-54 | Growth Inhibition Assay | IC50=11.4811 μM | SANGER | |||
| WM-115 | Growth Inhibition Assay | IC50=11.6824 μM | SANGER | |||
| COLO-684 | Growth Inhibition Assay | IC50=11.7267 μM | SANGER | |||
| HOP-62 | Growth Inhibition Assay | IC50=11.7508 μM | SANGER | |||
| NCI-H650 | Growth Inhibition Assay | IC50=11.8961 μM | SANGER | |||
| TE-11 | Growth Inhibition Assay | IC50=11.9315 μM | SANGER | |||
| COLO-679 | Growth Inhibition Assay | IC50=11.946 μM | SANGER | |||
| FTC-133 | Growth Inhibition Assay | IC50=12.0076 μM | SANGER | |||
| D-283MED | Growth Inhibition Assay | IC50=12.0569 μM | SANGER | |||
| SK-PN-DW | Growth Inhibition Assay | IC50=12.1902 μM | SANGER | |||
| BALL-1 | Growth Inhibition Assay | IC50=12.2662 μM | SANGER | |||
| GT3TKB | Growth Inhibition Assay | IC50=12.3074 μM | SANGER | |||
| HOP-92 | Growth Inhibition Assay | IC50=12.5233 μM | SANGER | |||
| M14 | Growth Inhibition Assay | IC50=13.0335 μM | SANGER | |||
| SKG-IIIa | Growth Inhibition Assay | IC50=13.0554 μM | SANGER | |||
| Becker | Growth Inhibition Assay | IC50=13.058 μM | SANGER | |||
| ES5 | Growth Inhibition Assay | IC50=13.1356 μM | SANGER | |||
| NCI-H2030 | Growth Inhibition Assay | IC50=13.2062 μM | SANGER | |||
| SNU-423 | Growth Inhibition Assay | IC50=13.381 μM | SANGER | |||
| CP50-MEL-B | Growth Inhibition Assay | IC50=13.6232 μM | SANGER | |||
| NCI-H1092 | Growth Inhibition Assay | IC50=13.7475 μM | SANGER | |||
| 8-MG-BA | Growth Inhibition Assay | IC50=13.7513 μM | SANGER | |||
| CAL-27 | Growth Inhibition Assay | IC50=14.0727 μM | SANGER | |||
| AGS | Growth Inhibition Assay | IC50=14.1319 μM | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | IC50=14.1488 μM | SANGER | |||
| BFTC-909 | Growth Inhibition Assay | IC50=14.5055 μM | SANGER | |||
| D-566MG | Growth Inhibition Assay | IC50=14.7706 μM | SANGER | |||
| MZ7-mel | Growth Inhibition Assay | IC50=15.1067 μM | SANGER | |||
| TE-5 | Growth Inhibition Assay | IC50=15.2333 μM | SANGER | |||
| 647-V | Growth Inhibition Assay | IC50=15.2705 μM | SANGER | |||
| DMS-114 | Growth Inhibition Assay | IC50=15.3291 μM | SANGER | |||
| ME-180 | Growth Inhibition Assay | IC50=15.4783 μM | SANGER | |||
| MS-1 | Growth Inhibition Assay | IC50=15.5623 μM | SANGER | |||
| NUGC-3 | Growth Inhibition Assay | IC50=15.6245 μM | SANGER | |||
| GB-1 | Growth Inhibition Assay | IC50=15.6437 μM | SANGER | |||
| LOXIMVI | Growth Inhibition Assay | IC50=15.8919 μM | SANGER | |||
| NCI-H1304 | Growth Inhibition Assay | IC50=15.8928 μM | SANGER | |||
| KURAMOCHI | Growth Inhibition Assay | IC50=15.971 μM | SANGER | |||
| SW1783 | Growth Inhibition Assay | IC50=16.0993 μM | SANGER | |||
| EGI-1 | Growth Inhibition Assay | IC50=16.5365 μM | SANGER | |||
| KGN | Growth Inhibition Assay | IC50=16.5586 μM | SANGER | |||
| PANC-03-27 | Growth Inhibition Assay | IC50=16.7662 μM | SANGER | |||
| RH-1 | Growth Inhibition Assay | IC50=16.825 μM | SANGER | |||
| HT-1376 | Growth Inhibition Assay | IC50=16.8446 μM | SANGER | |||
| ZR-75-30 | Growth Inhibition Assay | IC50=16.9361 μM | SANGER | |||
| TI-73 | Growth Inhibition Assay | IC50=16.9408 μM | SANGER | |||
| TK10 | Growth Inhibition Assay | IC50=17.0079 μM | SANGER | |||
| SW684 | Growth Inhibition Assay | IC50=17.0154 μM | SANGER | |||
| RPMI-8866 | Growth Inhibition Assay | IC50=17.0699 μM | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=17.5201 μM | SANGER | |||
| NCI-H2291 | Growth Inhibition Assay | IC50=18.4345 μM | SANGER | |||
| T47D | Growth Inhibition Assay | IC50=18.488 μM | SANGER | |||
| A204 | Growth Inhibition Assay | IC50=18.5452 μM | SANGER | |||
| HT-144 | Growth Inhibition Assay | IC50=18.7427 μM | SANGER | |||
| MDA-MB-361 | Growth Inhibition Assay | IC50=19.0714 μM | SANGER | |||
| HCC1806 | Growth Inhibition Assay | IC50=19.1591 μM | SANGER | |||
| NCI-H596 | Growth Inhibition Assay | IC50=19.6391 μM | SANGER | |||
| K-562 | Growth Inhibition Assay | IC50=19.8926 μM | SANGER | |||
| D-336MG | Growth Inhibition Assay | IC50=19.9322 μM | SANGER | |||
| SK-MEL-2 | Growth Inhibition Assay | IC50=20.1559 μM | SANGER | |||
| HEC-1 | Growth Inhibition Assay | IC50=20.4978 μM | SANGER | |||
| EW-13 | Growth Inhibition Assay | IC50=20.5443 μM | SANGER | |||
| Hs-578-T | Growth Inhibition Assay | IC50=20.5583 μM | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | IC50=20.5688 μM | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | IC50=20.6719 μM | SANGER | |||
| LAN-6 | Growth Inhibition Assay | IC50=21.0396 μM | SANGER | |||
| NCI-H1048 | Growth Inhibition Assay | IC50=21.2258 μM | SANGER | |||
| CW-2 | Growth Inhibition Assay | IC50=21.2705 μM | SANGER | |||
| HCC2157 | Growth Inhibition Assay | IC50=21.36 μM | SANGER | |||
| EW-22 | Growth Inhibition Assay | IC50=21.376 μM | SANGER | |||
| A253 | Growth Inhibition Assay | IC50=21.4481 μM | SANGER | |||
| BE-13 | Growth Inhibition Assay | IC50=21.6113 μM | SANGER | |||
| KINGS-1 | Growth Inhibition Assay | IC50=21.6316 μM | SANGER | |||
| ETK-1 | Growth Inhibition Assay | IC50=21.8152 μM | SANGER | |||
| NCI-H2452 | Growth Inhibition Assay | IC50=21.8647 μM | SANGER | |||
| HPAF-II | Growth Inhibition Assay | IC50=21.8923 μM | SANGER | |||
| D-542MG | Growth Inhibition Assay | IC50=21.9069 μM | SANGER | |||
| NCI-H630 | Growth Inhibition Assay | IC50=22.0296 μM | SANGER | |||
| TGBC11TKB | Growth Inhibition Assay | IC50=22.049 μM | SANGER | |||
| BCPAP | Growth Inhibition Assay | IC50=22.611 μM | SANGER | |||
| HLE | Growth Inhibition Assay | IC50=22.697 μM | SANGER | |||
| NCI-H727 | Growth Inhibition Assay | IC50=22.735 μM | SANGER | |||
| RD | Growth Inhibition Assay | IC50=22.7518 μM | SANGER | |||
| NCI-H522 | Growth Inhibition Assay | IC50=22.8431 μM | SANGER | |||
| CGTH-W-1 | Growth Inhibition Assay | IC50=23.0641 μM | SANGER | |||
| SK-LU-1 | Growth Inhibition Assay | IC50=23.4683 μM | SANGER | |||
| BB65-RCC | Growth Inhibition Assay | IC50=23.7863 μM | SANGER | |||
| HSC-3 | Growth Inhibition Assay | IC50=23.8527 μM | SANGER | |||
| SK-MES-1 | Growth Inhibition Assay | IC50=24.0161 μM | SANGER | |||
| DB | Growth Inhibition Assay | IC50=24.1028 μM | SANGER | |||
| HO-1-N-1 | Growth Inhibition Assay | IC50=24.3093 μM | SANGER | |||
| MKN1 | Growth Inhibition Assay | IC50=24.68 μM | SANGER | |||
| MN-60 | Growth Inhibition Assay | IC50=24.8519 μM | SANGER | |||
| 8505C | Growth Inhibition Assay | IC50=25.1845 μM | SANGER | |||
| COLO-320-HSR | Growth Inhibition Assay | IC50=25.2208 μM | SANGER | |||
| BB30-HNC | Growth Inhibition Assay | IC50=25.2483 μM | SANGER | |||
| KM12 | Growth Inhibition Assay | IC50=25.5807 μM | SANGER | |||
| NB13 | Growth Inhibition Assay | IC50=25.5898 μM | SANGER | |||
| HCC2998 | Growth Inhibition Assay | IC50=26.0283 μM | SANGER | |||
| U-118-MG | Growth Inhibition Assay | IC50=26.0808 μM | SANGER | |||
| NB10 | Growth Inhibition Assay | IC50=26.234 μM | SANGER | |||
| SK-LMS-1 | Growth Inhibition Assay | IC50=27.0704 μM | SANGER | |||
| SW1573 | Growth Inhibition Assay | IC50=27.11 μM | SANGER | |||
| LB373-MEL-D | Growth Inhibition Assay | IC50=27.1294 μM | SANGER | |||
| DK-MG | Growth Inhibition Assay | IC50=27.1817 μM | SANGER | |||
| RMG-I | Growth Inhibition Assay | IC50=27.2029 μM | SANGER | |||
| SW1088 | Growth Inhibition Assay | IC50=27.5042 μM | SANGER | |||
| SK-OV-3 | Growth Inhibition Assay | IC50=27.7593 μM | SANGER | |||
| KP-N-YN | Growth Inhibition Assay | IC50=27.8043 μM | SANGER | |||
| RPMI-7951 | Growth Inhibition Assay | IC50=28.2456 μM | SANGER | |||
| CaR-1 | Growth Inhibition Assay | IC50=28.5582 μM | SANGER | |||
| MKN7 | Growth Inhibition Assay | IC50=28.5964 μM | SANGER | |||
| CHP-212 | Growth Inhibition Assay | IC50=28.7401 μM | SANGER | |||
| KYSE-450 | Growth Inhibition Assay | IC50=28.8091 μM | SANGER | |||
| RXF393 | Growth Inhibition Assay | IC50=29.2906 μM | SANGER | |||
| P30-OHK | Growth Inhibition Assay | IC50=29.3048 μM | SANGER | |||
| Ca9-22 | Growth Inhibition Assay | IC50=29.4299 μM | SANGER | |||
| RT-112 | Growth Inhibition Assay | IC50=29.4611 μM | SANGER | |||
| ES1 | Growth Inhibition Assay | IC50=29.8544 μM | SANGER | |||
| HCE-4 | Growth Inhibition Assay | IC50=29.8786 μM | SANGER | |||
| AM-38 | Growth Inhibition Assay | IC50=30.0606 μM | SANGER | |||
| AsPC-1 | Growth Inhibition Assay | IC50=30.8053 μM | SANGER | |||
| TE-9 | Growth Inhibition Assay | IC50=30.8737 μM | SANGER | |||
| HuP-T4 | Growth Inhibition Assay | IC50=30.9638 μM | SANGER | |||
| LB2518-MEL | Growth Inhibition Assay | IC50=31.0744 μM | SANGER | |||
| NCI-H1703 | Growth Inhibition Assay | IC50=31.0905 μM | SANGER | |||
| NCI-H2228 | Growth Inhibition Assay | IC50=31.4651 μM | SANGER | |||
| SCC-4 | Growth Inhibition Assay | IC50=31.9181 μM | SANGER | |||
| KNS-81-FD | Growth Inhibition Assay | IC50=32.0128 μM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=32.0739 μM | SANGER | |||
| Daoy | Growth Inhibition Assay | IC50=32.0838 μM | SANGER | |||
| ES4 | Growth Inhibition Assay | IC50=32.3922 μM | SANGER | |||
| MHH-ES-1 | Growth Inhibition Assay | IC50=32.4872 μM | SANGER | |||
| C-33-A | Growth Inhibition Assay | IC50=32.7728 μM | SANGER | |||
| BHY | Growth Inhibition Assay | IC50=32.9495 μM | SANGER | |||
| Detroit562 | Growth Inhibition Assay | IC50=33.6657 μM | SANGER | |||
| EW-1 | Growth Inhibition Assay | IC50=33.9322 μM | SANGER | |||
| NCI-H1395 | Growth Inhibition Assay | IC50=34.0799 μM | SANGER | |||
| KM-H2 | Growth Inhibition Assay | IC50=36.4743 μM | SANGER | |||
| NCI-H520 | Growth Inhibition Assay | IC50=36.7541 μM | SANGER | |||
| D-392MG | Growth Inhibition Assay | IC50=37.3344 μM | SANGER | |||
| NOMO-1 | Growth Inhibition Assay | IC50=37.8089 μM | SANGER | |||
| TE-6 | Growth Inhibition Assay | IC50=38.124 μM | SANGER | |||
| HT-3 | Growth Inhibition Assay | IC50=38.4436 μM | SANGER | |||
| RPMI-8226 | Growth Inhibition Assay | IC50=38.9519 μM | SANGER | |||
| U251 | Growth Inhibition Assay | IC50=39.0124 μM | SANGER | |||
| GCT | Growth Inhibition Assay | IC50=39.1852 μM | SANGER | |||
| A431 | Growth Inhibition Assay | IC50=39.1894 μM | SANGER | |||
| TE-12 | Growth Inhibition Assay | IC50=39.2448 μM | SANGER | |||
| HMV-II | Growth Inhibition Assay | IC50=39.5047 μM | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | IC50=40.1502 μM | SANGER | |||
| SW13 | Growth Inhibition Assay | IC50=40.519 μM | SANGER | |||
| SF295 | Growth Inhibition Assay | IC50=40.8066 μM | SANGER | |||
| MDA-MB-157 | Growth Inhibition Assay | IC50=40.9462 μM | SANGER | |||
| TE-1 | Growth Inhibition Assay | IC50=41.8714 μM | SANGER | |||
| HuCCT1 | Growth Inhibition Assay | IC50=42.5289 μM | SANGER | |||
| KYSE-510 | Growth Inhibition Assay | IC50=43.1754 μM | SANGER | |||
| NCI-H358 | Growth Inhibition Assay | IC50=44.0304 μM | SANGER | |||
| SW900 | Growth Inhibition Assay | IC50=44.0758 μM | SANGER | |||
| CAS-1 | Growth Inhibition Assay | IC50=44.0991 μM | SANGER | |||
| TE-8 | Growth Inhibition Assay | IC50=44.5658 μM | SANGER | |||
| P12-ICHIKAWA | Growth Inhibition Assay | IC50=44.6112 μM | SANGER | |||
| YKG-1 | Growth Inhibition Assay | IC50=44.781 μM | SANGER | |||
| SNU-C2B | Growth Inhibition Assay | IC50=44.7903 μM | SANGER | |||
| LCLC-103H | Growth Inhibition Assay | IC50=44.8703 μM | SANGER | |||
| U-87-MG | Growth Inhibition Assay | IC50=45.1022 μM | SANGER | |||
| HAL-01 | Growth Inhibition Assay | IC50=45.1379 μM | SANGER | |||
| OVCAR-8 | Growth Inhibition Assay | IC50=45.3564 μM | SANGER | |||
| KYSE-150 | Growth Inhibition Assay | IC50=47.1052 μM | SANGER | |||
| OE33 | Growth Inhibition Assay | IC50=47.1429 μM | SANGER | |||
| CAL-62 | Growth Inhibition Assay | IC50=47.4068 μM | SANGER | |||
| TCCSUP | Growth Inhibition Assay | IC50=47.6264 μM | SANGER | |||
| H4 | Growth Inhibition Assay | IC50=47.6621 μM | SANGER | |||
| CP66-MEL | Growth Inhibition Assay | IC50=48.0704 μM | SANGER | |||
| SNB75 | Growth Inhibition Assay | IC50=48.1874 μM | SANGER | |||
| Mo-T | Growth Inhibition Assay | IC50=48.279 μM | SANGER | |||
| BT-549 | Growth Inhibition Assay | IC50=48.3729 μM | SANGER | |||
| IGR-1 | Growth Inhibition Assay | IC50=48.6645 μM | SANGER | |||
| NCI-H1299 | Growth Inhibition Assay | IC50=48.7248 μM | SANGER | |||
| ALL-PO | Growth Inhibition Assay | IC50=49.9268 μM | SANGER | |||
| CLL | Function assay | Inhibition of DNA-PK autophosphorylation at Ser2056 residue in human CLL cells by Western blot method, IC50 = 0.03 μM. | 22835870 | |||
| HeLa | Function assay | Inhibition of DNA-PK autophosphorylation at S2056 in human HeLa cells, EC50 = 0.212 μM. | 23855836 | |||
| CHO | Function assay | Inhibition of human ERG expressed in cisapride treated CHO cells by Ion Works assay, IC50 = 14 μM. | 23855836 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| INA-6 | Function assay | 10 uM | 4 hrs | Inhibition of heat shock response in human INA-6 cells assessed as reduction in HSF-1 mediated upregulation of the HSP72 protein expression at 10 uM preincubated for 4 hrs followed by HSP90 inhibitor and HSR inducer NVP-AUY922 addition measured after 4 hr | 28453931 | |
| INA-6 | Function assay | 10 uM | 4 hrs | Inhibition of heat shock response in human INA-6 cells assessed as reduction in HSF-1 mediated upregulation of the HSP72 mRNA expression at 10 uM preincubated for 4 hrs followed by HSP90 inhibitor and HSR inducer NVP-AUY922 addition measured after 4 hrs b | 28453931 | |
| INA-6 | Function assay | 10 uM | 4 hrs | Downregulation of NVP-AUY922-induced HSF-1 protein expression in human INA-6 cells at 10 uM preincubated for 4 hrs followed by NVP-AUY922 addition measured after 4 hrs by Western blot method | 28453931 | |
| INA-6 | Function assay | 10 uM | 4 hrs | Inhibition of NVP-AUY922-induced HSF-1 phosphorylation in human INA-6 cells at 10 uM preincubated for 4 hrs followed by NVP-AUY922 addition measured after 4 hrs by Western blot method | 28453931 | |
| INA-6 | Function assay | 10 uM | 4 hrs | Downregulation of NVP-AUY922-induced HSF-1 mRNA expression in human INA-6 cells at 10 uM preincubated for 4 hrs followed by NVP-AUY922 addition measured after 4 hrs by RT-PCR method | 28453931 | |
| Click to View More Cell Line Experimental Data | ||||||
Biological Activity
| Description | NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
| In vitro | ||||
| In vitro | NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, and doxorubicin in both SW620 and LoVo cells. [2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. [3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. [4] NU7441 increases levels of -induced γH2AX foci and correspondingly decreased -induced cell death in chronic lymphocytic leukemia cells. [5] NU7441 also inhibits -induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. [6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage[7]. |
|||
|---|---|---|---|---|
| Cell Research | Cell lines | SW620, LoVo, V3-YAC and V3 cells | ||
| Concentrations | 0.5 μM or 1 μM | |||
| Incubation Time | 17 hours | |||
| Method | The effect of NU7441 on cellular survival following exposure to doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min 137Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 105 per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441. |
|||
| Experimental Result Images | Methods | Biomarkers | Images | PMID |
| Western blot | p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51 p-mTOR(Ser2448) / mTOR / p-S6K(Thr389) |
|
29344644 | |
| In Vivo | ||
| In vivo | NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases induced tumor growth delay 2-fold in mice bearing SW620 xenografts. [2] |
|
|---|---|---|
| Animal Research | Animal Models | Female rude mice bearing SW620 xenografts |
| Dosages | 10 mg/kg | |
| Administration | Intraperitoneally administrated | |
Chemical Information & Solubility
| Molecular Weight | 413.49 | Formula | C25H19NO3S |
| CAS No. | 503468-95-9 | SDF | Download NU7441 (KU-57788) SDF |
| Smiles | C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56 | ||
| Storage (From the date of receipt) | |||
|
In vitro |
DMSO : 5 mg/mL ( (12.09 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.) Water : Insoluble Ethanol : Insoluble |
Molecular Weight Calculator |
|
In vivo Add solvents to the product individually and in order. |
In vivo Formulation Calculator |
||||
Preparing Stock Solutions
Molarity Calculator
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
mg/kg
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
* Indicates a Required Field
Frequently Asked Questions
Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.
Tags: buy NU7441 (KU-57788) | NU7441 (KU-57788) supplier | purchase NU7441 (KU-57788) | NU7441 (KU-57788) cost | NU7441 (KU-57788) manufacturer | order NU7441 (KU-57788) | NU7441 (KU-57788) distributor
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.